



# Antagomir to prevent cardiac arrhythmia (2019-069)

**IP Status:** Provisional Patent Application Filed

## Applications

- Therapeutic (alone or in combination) for cardiac arrhythmias
- Research tool to knock-down miR-448 and or upregulate SCN5A
- Cancer therapeutic (for cancers where miR-448 is relevant)

## Technology Overview

Arrhythmic cardiomyopathy can cause severe problems including cardiac arrest and death. Unfortunately, many of the therapeutics to treat arrhythmias can actually have pro-arrhythmic side effects. This technology is an antagomir targeting miR-448 (anti-miR-448), a microRNA linked to the downregulation of the sodium channel SCN5A. Relieving the inhibition of miR-448 facilitates the upregulation of SCN5A, which is protective against arrhythmia, while bypassing the potential pro-arrhythmic side-effects of existing therapies.

## Phase of Development

### TRL: 3

In vitro and in vivo testing.

## Desired Partnerships

This technology is now available for:

- License
- Sponsored research
- Co-development

Please contact our office to share your business' needs and learn more.

**Researchers:** Sam Dudley, MD, PhD , Professor of Medicine, Cardiovascular Division, Medical School

## Technology ID

2019-069

## Category

Life Sciences/Biologics  
Life Sciences/Human Health  
Life Sciences/Pharmaceuticals  
Life Sciences/Research Tools

## View online page

